Multicentric Phase I/II Study for the Efficacy of a Combination of Rituximab, Gemcitabine and Oxaliplatin in Relapsed/Refractory Indolent Lymphoma.

Trial Profile

Multicentric Phase I/II Study for the Efficacy of a Combination of Rituximab, Gemcitabine and Oxaliplatin in Relapsed/Refractory Indolent Lymphoma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2015

At a glance

  • Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Rituximab (Primary)
  • Indications B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Acronyms R-GO
  • Most Recent Events

    • 13 Mar 2012 Actual patient number (56) added as reported by ClinicalTrials.gov.
    • 13 Mar 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 18 Aug 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top